期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

2012美国疾病预防控制中心耐碳青霉烯类肠杆菌控制指南简介 被引量：26

暂未订购
导出
摘要 碳青霉烯类药物是治疗革兰阴性杆菌感染特别是肠杆菌科细菌的最强效-內酰胺类药物[1]。一旦碳青霉烯类药物耐药，临床治疗此类菌株感染将面临极大困难。目前，碳青霉烯类药物耐药的肠杆菌科菌（carbapenem-resistant Enterobacteriaceae， CRE）已在很多国家出现和报道[2-5]。在美国地区传播的CRE耐药表型多为产肺炎克雷伯菌碳青霉烯酶（Klebsiella pneumonia carbapenemase，KPC），其流行特征具有区域甚至院际差异性。美国自2009年以来，除产KPC肠杆菌科菌外，已分离到多种不同的产金属β内酰胺酶菌株，包括NDM型、VIM型及IMP型。这些产金属β内酰胺酶菌株在其他国家更为普遍，而在美国一般是在其他流行区域接受过治疗的患者体内发现。
作者 代强 郑波
机构地区 北京大学第一医院临床药理研究所
出处 《中国医学前沿杂志（电子版）》 2013年第8期30-31,共2页 Chinese Journal of the Frontiers of Medical Science(Electronic Version)
关键词 耐碳青霉烯类 细菌 CRE 肠道细菌 肠杆菌 美国疾病预防控制中心 控制指南
分类号 R446.5 [医药卫生—诊断学]
  • 相关文献

参考文献6

  • 1Rahal JJ. The role of carbapenems in initial therapy for serious Gram-negative infections[J].{H}CRITICAL CARE,2008,(Suppl 4):S5.
  • 2Yigit H,Queenan AM,Anderson GJ. Novel carbapenem-hydrolyzing beta-lactamase,KPC-1,from a carbapenem-resistant strain of Klebsiella pneumoniae[J].{H}Antimicrobial Agents and Chemotherapy,2001,(04):1151-1161.
  • 3Vatopoulos A. High rates of metallo-beta-lactamase-producing Klebsiella pneumoniae in Greece-a review of the current evidence[J].Euro Surveill,2008,(04):8023.
  • 4Oteo J,Delgado-Iribarren A,Vega D. Emergence of imipenem resistance in clinical Escherichia coli during therapy[J].{H}International Journal of Antimicrobial Agents,2008,(06):534-537.
  • 5Kaczmarek FM,Dib-Hajj F,Shang W. High-level carbapenem resistance in a Klebsiella pneumoniae clinical isolate is due to the combination of bla(ACT-1)beta-lactamase production,porin OmpK35/36 insertional inactivation,and down-regulation of the phosphate transport porin phoe[J].{H}Antimicrobial Agents and Chemotherapy,2006,(10):3396-3406.
  • 6徐英春,肖永红,卓超,郑波,王辉,杨启文.中国碳青霉烯类耐药肠杆菌科细菌的流行病学和防控策略[J].中国执业药师,2013(4):3-8. 被引量：92

二级参考文献32

  • 1骆俊,朱德妹,徐晓刚,吴卫红,王明贵,张婴元,汪复.泛耐药弗劳地柠檬酸杆菌产β内酰胺酶及同源性[J].中华传染病杂志,2006,24(5):291-295. 被引量：20
  • 2Rahal JJ. The role of carbapenems in initial therapy for serious Gram-negative infections[J]. Crit Care, 2008,12 ($4) : 5.
  • 3Yigit H, Queenan AM, Anderson GJ, et al. Novel earbapen- em-hydrolyzing beta-laetamase, KPC-1, from a earbapenem-re- sistant strain of Klebsiella pneumoniae [J]. Antimierob Agents Chemother,2001,45(4) : 1151-1161.
  • 4Vatopoulos A. High rates of metallo-beta-lactamase-producing Klebsiella pneumoniae in Greece-a review of the current evi- dence[J]. Euro Surveill, 2008,13 (4), pii : 8023.
  • 5Oteo J, Delgado-Iribarren A, Vega D, et al. Emergence of imipen- em resistance in clinical Escherichia coli during therapy[J], lnt J Antimicrob Agents, 2008,32 (6) : 534-537.
  • 6Kaczmarek FM, Dib-Hajj F, Shang W, et al. High-level carbapen- em resistance in a Klebsiella pneumoniae clinical isolate is due to the combination of bla (ACT-1) beta-lactamase production ,porin OmpK35/36 insertional inactivation, and down-regulation of the phosphate transport porin phoe [J]. Antimicrob Agents Chemoth- er, 2006,50 (10) : 3396-3406.
  • 7Queenan AM, Bush K. Carbapenemases: the versatile beta-lacta- mases[J]. Clin Mierobiol Rev, 2007,20 (3) : 440-458.
  • 8Yigit H, Anderson G J, Biddle JW, et al. Carbapenem resistance in a clinical isolate of Enterobacter aerogenes is associated with de- creased expression of OmpF and OmpC porin analogs[J]. Antimi- crob Agents Chemother, 2002,46 ( 12 ) : 3817-3822.
  • 9Villar HE, Danel F, Livermore DM. Permeability to carbapenems of Proteus mirabilis mutants selected for resistance to imipenem or other beta-lactams[J]. J Antimicrob Chemother, 1997,40 (3) : 365-370.
  • 10Castanheira M, Mendes RE, Woosley LN, et al. Trends in car- bapenemase-producing Escherichia coli and Klebsiella spp. from Europe and the Americas : report from the SENTRYantimicrobial surveillance programme (2007-09)[J]. J Antimicrob Chemother, 2011,66(6) : 1409-1411.

共引文献91

同被引文献193

  • 1上官丽娟,王海龙,尚晶,王智军,侯苗苗,薛岚平.宏基因二代测序在中枢神经系统感染性疾病诊断中的应用[J].武警医学,2022,33(6):472-475. 被引量：9
  • 2李坤,史伟峰,季云,王玉月,糜祖煌.膜孔蛋白基因缺失与肺炎克雷伯菌耐碳青霉烯类抗生素的关系[J].中华临床感染病杂志,2011,4(3). 被引量：13
  • 3Rahal JJ. The role of carbapenems in initial therapy for se- rious Gram-negative infections [J]. Crit Care, 2008, 12 (Suppl 4) : S5.
  • 4Health Protection Agency. Guidance on carbapenem re- sistance producers [EB/OL]. [2011-01-28]. http : //www. hpa.org.uk/web/HPAweb&Page&HPAwebAutoListName/ Page/1294740725255.
  • 5Maniaci V, Dauber A, Weiss S, et al. Procalcitonin in young febrile infants for the detection of serious bacterial infections [J]. Pediatrics, 2008, 122(4): 701-710.
  • 6BorerA, Saidel-Odes L, Riesenberg K, et al. Attributable mortality rate for carbapenem-resistant Klebsiella pneumoni- ae bacteremia [J]. Infect Control Hosp Epidemiol, 2009, 30(10): 972-976.
  • 7Chang HJ, Hsu PC, Yang CC, et al. Risk factors and outcomes of carbapenem-nonsusceptible Escherichia coli bacteremia: a matched case-control study [J]. J Microbiol Immunollnfect, 2011, 44(2): 125-130.
  • 8ApisarnthanarakA, Pinitchai U, Thongphubeth K, et al. A multifaceted intervention to reduce pandrug-resistant Aeinetobaeter baumannii colonization and infection in 3 intensive care units in a Thai tertiary care center: a 3-year study [J]. Clin Infect Dis, 2008, 47(6): 760-767.
  • 9Chhapola V, Brar R. Impact of an educational intervention on hand hygiene compliance and infection rate in a deve- loping country neonatal intensive care unit [J]. Int J Nurs Pract, 2014.[Epub ahead of print].
  • 10Rogers E, Alderdice F, McCall E, et al. Reducing noso- comial infections in neonatal intensive care[J]. J Matern FetalNeonatalMed, 2010, 23(9): 1039-1046.

引证文献26

二级引证文献184

中国医学前沿杂志（电子版）
2013年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部